Abstract
The registration of follow-on biologics will depend on the availability of data demonstrating comparability with a reference product. It is recognised that measurement of relative immunogenicity will be an important component of the product comparability assessment. The way in which this is done will depend on a multidimensional risk-based approach that considers the probability of generating an immune response relative to the consequences of such a response. This paper presents principles and practical guidance for constructing a risk assessment, building on the experience gained for a variety of biopharmaceutical products. This includes the use of preclinical models and validated bioanalytical methods. Ultimately, post-marketing monitoring will be required to evaluate more fully the risk in representative settings, given the multifactorial nature of the potential immunogenicity of different therapeutic proteins.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
